Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review.

ABSTRACT:

Background and objective

Lung cancer, mainly non-small cell lung cancer (NSCLC), is a serious threat to human life. In particular, the prognosis for advanced patients is poor, with the 5-year survival rate being exceedingly low. In recent years, immune checkpoint inhibition has changed the pattern of the treatment of a variety of cancers, including lung cancer; however, not all patients can benefit from immunotherapy, and thus finding the right biomarkers is particularly important for guiding precise treatment. Programmed death-ligand 1 (PD-L1) expression is one of the most valuable biomarkers for predicting the efficacy of lung cancer immunotherapy. Several studies have confirmed that patients with high PD-L1 expression are more likely to benefit from immunotherapy, but there is a

SUBMITTER: Bai Y 

PROVIDER: S-EPMC10938091 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature